Study Evaluating Venlafaxine ER in Patients With Panic Disorder - Full Text View

Study Evaluating Venlafaxine ER in Patients With Panic Disorder

This study is ongoing, but not recruiting participants.

Sponsored by:	Wyeth
Information provided by:	Wyeth
ClinicalTrials.gov Identifier:	NCT00044772

Purpose

The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.

Condition	Intervention	Phase
Panic Disorder	Drug: Venlafaxine ER	Phase III

MedlinePlus related topics:

Panic Disorder

ChemIDplus related topics:

Paroxetine Paroxetine hydrochloride Paroxetine Mesylate Venlafaxine Venlafaxine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	A Double-Blind, Placebo-Controlled, Parallel-Group Comparison of Venlafaxine Extended-Release Capsules and Paroxetine in Outpatients With Panic Disorder

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1
Have sufficient symptoms to require anxiolytic drug therapy
Have a score ≥4 on the Clinical Global Impressions Scale (CGI) severity of illness item at screening and baseline

Exclusion Criteria:

Known hypersensitivity to venlafaxine (IR or ER), related compounds, or paroxetine
History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma [except basal cell epithelioma], uncontrolled hypertension)
Clinically important abnormality on screening physical examination, vital signs, electrocardiogram (ECG), laboratory tests or urine drug screen

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00044772

Sponsors and Collaborators

Wyeth

Investigators


Study Director:	Medical Monitor, MD	Wyeth

More Information

Study ID Numbers:	0600B5-399
First Received:	September 4, 2002
Last Updated:	May 18, 2006
ClinicalTrials.gov Identifier:	NCT00044772
Health Authority:	United States: Food and Drug Administration

Keywords provided by Wyeth:

Panic

Disorder

Study placed in the following topic categories:

Panic Disorder

Anxiety Disorders

Mental Disorders

Venlafaxine

Paroxetine

Serotonin

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors

Neurotransmitter Agents

Disease

Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs

Psychotropic Drugs

Serotonin Uptake Inhibitors

Pharmacologic Actions

Pathologic Processes

Serotonin Agents

Therapeutic Uses

Antidepressive Agents, Second-Generation

Central Nervous System Agents

Antidepressive Agents

ClinicalTrials.gov processed this record on August 28, 2008